See every side of every news story
Published loading...Updated

Getting to Complete Response With Less Toxicity in HER2-Positive Early Breast Cancer

Summary by MedPage Today
(MedPage Today) -- In the DESTINY-Breast11 (DB11) trial, trastuzumab deruxtecan (T-DXd, Enhertu), followed by the taxane paclitaxel (Taxol), trastuzumab (Herceptin), and pertuzumab (Perjeta) in combination (THP), improved pathologic complete response...

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MedPage Today broke the news in New York, United States on Monday, July 7, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.